---
title: "Tirzepatide in Older Adults with Type 2 Diabetes: Real-World Hypoglycemia and Weight Outcomes"
id: "pubmed-42457543"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42457543"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42457543/"
doi: "10.1507/endocrj.EJ26-0246"
published_at: "2026-11-02T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Tirzepatide in Older Adults with Type 2 Diabetes: Real-World Hypoglycemia and Weight Outcomes
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42457543
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42457543/)
- **DOI:** [10.1507/endocrj.EJ26-0246](https://doi.org/10.1507%2Fendocrj.EJ26-0246)
- **Published At:** 2026-11-02T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Investigators performed a secondary analysis of the Hokkaido-TZP study (UMIN000056962) focusing on patients aged ≥65 years receiving **tirzepatide** in routine practice. - The safety analysis set included 213 patients; 11 (5.2%) discontinued treatment because of adverse events, most commonly gastrointestinal symptoms. - The effectiveness analysis set comprised 199 patients with a mean age of 71.3 years and baseline **HbA1c** 7.79%. - Both the Young-old (65–74 years) and Old-old (≥75 years) groups showed statistically significant reductions in **HbA1c** and body mass index at 6 months, investigators reported. - At baseline, 148 patients (74.4%) were taking agents linked to **hypoglycemia** risk (insulin, sulfonylureas, or glinides); 66.9% of these reached **HbA1c** <7.0% during follow-up. - Physicians proactively adjusted concomitant hypoglycemia-inducing medications in 39.2% of users; despite dose reductions, the subgroup experienced HbA1c declines comparable to the overall cohort, and no severe **hypoglycemia** was reported. - Body-weight reduction was significant overall; larger weight loss occurred in GLP-1 receptor agonist–naïve patients and those taking fewer hypoglycemia-risk agents, authors noted. - The dataset indicated a tendency toward lower **tirzepatide** doses among patients who achieved greater weight loss, though the source did not report detailed dosing algorithms. - Authors concluded that while **tirzepatide** is effective in older adults, safety optimization — through preemptive reductions in secretagogues and close monitoring — is necessary to avoid excessive HbA1c and weight declines in this vulnerable population.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42457543/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42457543%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42457543/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42457543/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42457543/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42457543/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42457543/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42457543/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42457543%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42457543%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42457543/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42457543/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42457543/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42457543/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![J-STAGE, Japan Science and Technology Information Aggregator, Electronic full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.jstage.jst.go.jp-pub-images-pubmed-logo.gif) J-STAGE, Japan Science and Technology Information Aggregator, Electronic ](https://doi.org/10.1507/endocrj.EJ26-0246 "See full text options at J-STAGE, Japan Science and Technology Information Aggregator, Electronic") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42457543/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42457543/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42457543/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42457543/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42457543/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42457543/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42457543/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42457543/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42457543/#linkout) Title & authors Abstract Similar articles MeSH terms Substances Related information LinkOut - more resources Endocr J Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Endocr+J%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Endocr+J%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42457543/) . 2026 Nov 2;73(11):1261-1269. doi: 10.1507/endocrj.EJ26-0246. Epub 2026 Jul 14. # Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters [Hiroya Kitsunai](https://pubmed.ncbi.nlm.nih.gov/?term=Kitsunai+H&cauthor_id=42457543)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#full-view-affiliation-1 "Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido 078-8510, Japan."), [Fumika Maruyama](https://pubmed.ncbi.nlm.nih.gov/?term=Maruyama+F&cauthor_id=42457543)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#full-view-affiliation-1 "Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido 078-8510, Japan."), [Yukie Miyano](https://pubmed.ncbi.nlm.nih.gov/?term=Miyano+Y&cauthor_id=42457543)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#full-view-affiliation-2 "Sapporo Diabetes and Thyroid Clinic, Hokkaido 060-0807, Japan."), [Tomoe Abe](https://pubmed.ncbi.nlm.nih.gov/?term=Abe+T&cauthor_id=42457543)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#full-view-affiliation-2 "Sapporo Diabetes and Thyroid Clinic, Hokkaido 060-0807, Japan."), [Hiroyoshi Kurihara](https://pubmed.ncbi.nlm.nih.gov/?term=Kurihara+H&cauthor_id=42457543)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#full-view-affiliation-3 "Kurihara Clinic, Hokkaido 004-0053, Japan."), [Ken Tsuji](https://pubmed.ncbi.nlm.nih.gov/?term=Tsuji+K&cauthor_id=42457543)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#full-view-affiliation-4 "Department of Diabetology and Endocrinology, Japanese Red Cross Asahikawa Hospital, Hokkaido 070-0061, Japan."), [Atsuko Abiko](https://pubmed.ncbi.nlm.nih.gov/?term=Abiko+A&cauthor_id=42457543)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#full-view-affiliation-4 "Department of Diabetology and Endocrinology, Japanese Red Cross Asahikawa Hospital, Hokkaido 070-0061, Japan."), [Yoshihiro Miyamoto](https://pubmed.ncbi.nlm.nih.gov/?term=Miyamoto+Y&cauthor_id=42457543)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#full-view-affiliation-5 "Department of Diabetology and Endocrinology, Asahikawa City Hospital, Hokkaido 070-8610, Japan."), [Reiko Homma](https://pubmed.ncbi.nlm.nih.gov/?term=Homma+R&cauthor_id=42457543)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#full-view-affiliation-6 "Department of Metabolism and Endocrinology, Asahikawa-Kosei General Hospital, Hokkaido 078-8211, Japan."), [Akinobu Nakamura](https://pubmed.ncbi.nlm.nih.gov/?term=Nakamura+A&cauthor_id=42457543)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#full-view-affiliation-7 "Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8648, Japan."), [Hiroshi Nomoto](https://pubmed.ncbi.nlm.nih.gov/?term=Nomoto+H&cauthor_id=42457543)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#full-view-affiliation-1 "Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido 078-8510, Japan."); [Hokkaido-TZP Study Group](https://pubmed.ncbi.nlm.nih.gov/?term=Hokkaido-TZP+Study+Group%5BCorporate+Author%5D) Affiliations Expand ### Affiliations * 1 Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido 078-8510, Japan. * 2 Sapporo Diabetes and Thyroid Clinic, Hokkaido 060-0807, Japan. * 3 Kurihara Clinic, Hokkaido 004-0053, Japan. * 4 Department of Diabetology and Endocrinology, Japanese Red Cross Asahikawa Hospital, Hokkaido 070-0061, Japan. * 5 Department of Diabetology and Endocrinology, Asahikawa City Hospital, Hokkaido 070-8610, Japan. * 6 Department of Metabolism and Endocrinology, Asahikawa-Kosei General Hospital, Hokkaido 078-8211, Japan. * 7 Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8648, Japan. * PMID: **42457543** * DOI: [ 10.1507/endocrj.EJ26-0246 ](https://doi.org/10.1507/endocrj.ej26-0246) Free article Item in Clipboard # Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters Hiroya Kitsunai et al. Endocr J. 2026. Free article Show details Display options Display options Format Abstract PubMed PMID Endocr J Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Endocr+J%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Endocr+J%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42457543/) . 2026 Nov 2;73(11):1261-1269. doi: 10.1507/endocrj.EJ26-0246. Epub 2026 Jul 14. ### Authors [Hiroya Kitsunai](https://pubmed.ncbi.nlm.nih.gov/?term=Kitsunai+H&cauthor_id=42457543)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#short-view-affiliation-1 "Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido 078-8510, Japan."), [Fumika Maruyama](https://pubmed.ncbi.nlm.nih.gov/?term=Maruyama+F&cauthor_id=42457543)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#short-view-affiliation-1 "Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido 078-8510, Japan."), [Yukie Miyano](https://pubmed.ncbi.nlm.nih.gov/?term=Miyano+Y&cauthor_id=42457543)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#short-view-affiliation-2 "Sapporo Diabetes and Thyroid Clinic, Hokkaido 060-0807, Japan."), [Tomoe Abe](https://pubmed.ncbi.nlm.nih.gov/?term=Abe+T&cauthor_id=42457543)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#short-view-affiliation-2 "Sapporo Diabetes and Thyroid Clinic, Hokkaido 060-0807, Japan."), [Hiroyoshi Kurihara](https://pubmed.ncbi.nlm.nih.gov/?term=Kurihara+H&cauthor_id=42457543)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#short-view-affiliation-3 "Kurihara Clinic, Hokkaido 004-0053, Japan."), [Ken Tsuji](https://pubmed.ncbi.nlm.nih.gov/?term=Tsuji+K&cauthor_id=42457543)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#short-view-affiliation-4 "Department of Diabetology and Endocrinology, Japanese Red Cross Asahikawa Hospital, Hokkaido 070-0061, Japan."), [Atsuko Abiko](https://pubmed.ncbi.nlm.nih.gov/?term=Abiko+A&cauthor_id=42457543)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#short-view-affiliation-4 "Department of Diabetology and Endocrinology, Japanese Red Cross Asahikawa Hospital, Hokkaido 070-0061, Japan."), [Yoshihiro Miyamoto](https://pubmed.ncbi.nlm.nih.gov/?term=Miyamoto+Y&cauthor_id=42457543)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#short-view-affiliation-5 "Department of Diabetology and Endocrinology, Asahikawa City Hospital, Hokkaido 070-8610, Japan."), [Reiko Homma](https://pubmed.ncbi.nlm.nih.gov/?term=Homma+R&cauthor_id=42457543)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#short-view-affiliation-6 "Department of Metabolism and Endocrinology, Asahikawa-Kosei General Hospital, Hokkaido 078-8211, Japan."), [Akinobu Nakamura](https://pubmed.ncbi.nlm.nih.gov/?term=Nakamura+A&cauthor_id=42457543)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#short-view-affiliation-7 "Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8648, Japan."), [Hiroshi Nomoto](https://pubmed.ncbi.nlm.nih.gov/?term=Nomoto+H&cauthor_id=42457543)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42457543/#short-view-affiliation-1 "Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido 078-8510, Japan."); [Hokkaido-TZP Study Group](https://pubmed.ncbi.nlm.nih.gov/?term=Hokkaido-TZP+Study+Group%5BCorporate+Author%5D) ### Affiliations * 1 Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido 078-8510, Japan. * 2 Sapporo Diabetes and Thyroid Clinic, Hokkaido 060-0807, Japan. * 3 Kurihara Clinic, Hokkaido 004-0053, Japan. * 4 Department of Diabetology and Endocrinology, Japanese Red Cross Asahikawa Hospital, Hokkaido 070-0061, Japan. * 5 Department of Diabetology and Endocrinology, Asahikawa City Hospital, Hokkaido 070-8610, Japan. * 6 Department of Metabolism and Endocrinology, Asahikawa-Kosei General Hospital, Hokkaido 078-8211, Japan. * 7 Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8648, Japan. * PMID: **42457543** * DOI: [ 10.1507/endocrj.EJ26-0246 ](https://doi.org/10.1507/endocrj.ej26-0246) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract In an aging society, the establishment of safe and effective treatment strategies for older patients with type 2 diabetes is crucial. We performed a secondary analysis of the Hokkaido-TZP study (UMIN000056962), evaluating the real-world outcomes of tirzepatide in patients aged ≥65 years. Of 213 patients in the safety analysis set, 11 (5.2%) discontinued treatment because of adverse events, primarily gastrointestinal symptoms. In the effectiveness analysis set (n = 199; mean age 71.3 years, glycated hemoglobin [HbA1c] 7.79%), tirzepatide significantly reduced both HbA1c and body mass index over 6 months in the Young-old (65-74 years) and Old-old (≥75 years) groups. Notably, even among the 148 patients (74.4%) using agents associated with a risk of hypoglycemia (insulin, sulfonylureas, or glinides) at baseline, a substantial proportion (66.9%) achieved an HbA1c <7.0%. The physicians proactively adjusted these concomitant medications in 39.2% of users, but despite these preemptive reductions, this subgroup still achieved a reduction in HbA1c comparable to that of the entire cohort, and no severe hypoglycemia was reported. A significant reduction in body weight occurred, and this was more pronounced in glucagon-like peptide-1 receptor agonist-naïve patients and those taking fewer hypoglycemia-inducing agents. Furthermore, the tirzepatide dose tended to be lower in the patients who achieved greater weight loss. These findings suggest that although tirzepatide is highly effective, even in older adults, its safety must be optimized through preemptive reductions in the doses of concomitantly administered secretagogues and careful monitoring, to prevent excessive reductions in HbA1c and weight loss in this vulnerable population. **Keywords:** Hypoglycemia risk; Older patient; Real-world clinical evidence; Tirzepatide; Type 2 diabetes. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes. ](https://pubmed.ncbi.nlm.nih.gov/40537987/) Ciudin A, Johansson E, Zimner-Rapuch S, Dimitriadis GK, Bertrand M, Curteis T, Clark LJ, Fan L, Sapin H, Bergmann JF.Ciudin A, et al.Diabetes Obes Metab. 2025 Sep;27(9):4709-4719. doi: 10.1111/dom.16508. Epub 2025 Jun 19.Diabetes Obes Metab. 2025.PMID: 40537987Free PMC article.Clinical Trial. * [ Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes. ](https://pubmed.ncbi.nlm.nih.gov/41066072/) Hoog MM, Vallarino C, Maldonado JM, Grabner M, Teng CC, Terrell K, Richard EL.Hoog MM, et al.Diabetes Ther. 2025 Nov;16(11):2237-2256. doi: 10.1007/s13300-025-01794-9. Epub 2025 Oct 9.Diabetes Ther. 2025.PMID: 41066072Free PMC article. * [ Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. ](https://pubmed.ncbi.nlm.nih.gov/40196933/) Thomsen RW, Mailhac A, Løhde JB, Pottegård A.Thomsen RW, et al.Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8.Diabetes Obes Metab. 2025.PMID: 40196933Free PMC article.Review. * [ Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. ](https://pubmed.ncbi.nlm.nih.gov/35579691/) Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E.Karagiannis T, et al.Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17.Diabetologia. 2022.PMID: 35579691Free PMC article. * [ Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. ](https://pubmed.ncbi.nlm.nih.gov/37786396/) Rosenstock J, Frías JP, Rodbard HW, Tofé S, Sears E, Huh R, Fernán
## Related Clinical Research

- [Orforglipron Added to Titrated Insulin Glargine Improves Glycemic Control and Weight in Type 2 Dia](https://medichelpline.com/clinical-feed/pubmed-42251769.md) (DOI: 10.1001/jama.2026.9512)
- [Resistance exercise preserves lean mass during tirzepatide therapy for obesity](https://medichelpline.com/clinical-feed/nature-1-resistance-exercise-to-attenuate-lean-mass-loss-during-tirzepatide-therapy-for.md)
- [GLP-1 receptor agonist weight loss in breast cancer patients on endocrine therapy](https://medichelpline.com/clinical-feed/pubmed-42932003.md) (DOI: 10.1007/s10549-026-08096-z)
- [Semaglutide preserves kidney function in type 2 diabetes: mechanisms from the REMODEL randomized t](https://medichelpline.com/clinical-feed/nature-1-effects-of-semaglutide-on-kidney-disease-in-type-2-diabetes-a-randomized.md)
- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.